

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

50-801

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-709

Connetics Corporation
Attn: Sharon Hall, Senior Director, Regulatory Affairs
3290 West Bayshore Road
Palo Alto, CA 94303

Dear Ms. Hall:

Please refer to your new drug application (NDA) dated December 22, 2003, received December 24, 2004, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Evoclin (clindamycin phosphate) Foam, 1%.

We acknowledge receipt of your submissions dated January 16, February 9, April 8 and 29, May 5, July 28, August 4 and 6, September 13, 17, and 20, and October 8, 13, and 14, 2004.

This new drug application provides for the use of Evoclin (clindamycin phosphate) Foam, 1% for topical administration in the treatment of acne vulgaris.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, immediate container and carton labels). Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-709.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Dermatologic and Dental Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Melinda Harris, M.S., Regulatory Project Manager, at (301) 827-2020.

Sincerely,

(See appended electronic signature page)

Jonathan Wilkin, M.D.
Director
Division of Dermatologic and Dental Drug
Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure